Regulus Therapeutics Inc. has received $-0.36 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 4 Financial Advisor in the Stock Trading Firms. Among 4 Analysts, Bottom line EPS Estimate for the current quarter is $-0.39 while the top line estimate is $-0.34 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -157.14%.
Regulus Therapeutics Inc. reported better than expected with a surprise EPS of 5.13% or $0.02 during its most recent quarterly earnings. The Actual EPS was $-0.37 compared to the Estimated EPS of $-0.39.
In the last quarter, Regulus Therapeutics Inc. reported Annual Earnings of $-0.37. Based on the filings, last years Annual Earnings was, $-1.04. In the last Quarter, RGLS reported a surprise Earnings per Share of 5.13% . The consensus estimate for current quarter is $-0.36 and for the current fiscal year, the estimate is $-1.54. For the Next fiscal year, the estimate is $-1.51 based on the consensus.
Regulus Therapeutics Inc. (NASDAQ:RGLS) stock ended Tuesday session in the red zone in a volatile trading. The stock closed down 0.1 points or 7.69% at $1.2 with 2,228,360 shares getting traded. Post opening the session at $1.3, the shares hit an intraday low of $1.15 and an intraday high of $1.325 and the price was in this range throughout the day. The company has a market cap of $64 million and the number of outstanding shares has been calculated to be 52,923,305 shares. The 52-week high of Regulus Therapeutics Inc. (NASDAQ:RGLS) is $8.9 and the 52-week low is $1.05.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.